SCHEMBL3848969

SCHEMBL3848969

CCCCCN[C@@H](Cc1c[nH]c2ccccc12)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
ALOX15 P16050 1/20 0.61
BCHE P06276 4/20 0.61
ACE P12821 3/20 0.60
KCNA5 P22460 1/20 0.59
KDM4E B2RXH2 1/20 0.57
APAF1 O14727 1/20 0.57
POLB P06746 1/20 0.57
MAPT P10636 1/20 0.57
RECQL P46063 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
ITGB2 P05107 1/20 0.57
ICAM1 P05362 1/20 0.57
ITGAL P20701 1/20 0.57
MMP1 P03956 1/20 0.57
MMP2 P08253 1/20 0.57
MMP8 P22894 1/20 0.57
CCKBR P32239 1/20 0.56
ECE1 P42892 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848569 1.00 MEN1 (0.63) MEN1KMT2AALOX15BCHEACE
SCHEMBL3848966 1.00 MEN1 (0.63) MEN1KMT2AALOX15BCHEACE
SCHEMBL6244061 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL6244059 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL6245120 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL28377319 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL6245123 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL8384762 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
SCHEMBL8384759 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE
Water SCHEMBL27944928 0.99 MEN1 (0.62) MEN1KMT2AALOX15BCHEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112920092-B Prodrugs of glutamine analogues 约翰霍普金斯大学 2024-04-26 CN claimed
US-20220233502-A1 COMPOSITION FOR PREVENTING OR TREATING ASTHMA, RHINITIS OR CONJUNCTIVITIS, COMPRISING N-ACYL AMINO ACID AS ACTIVE INGREDIENT STEMDR INC. (KR) 2022-07-28 US claimed
CN-114340612-A Composition for preventing or treating asthma, rhinitis or conjunctivitis comprising N-acylamino acid as active ingredient 斯特姆德公司 2022-04-12 CN claimed
EP-3977990-A1 COMPOSITION FOR PREVENTING OR TREATING ASTHMA, RHINITIS OR CONJUNCTIVITIS, COMPRISING N-ACYL AMINO ACID AS ACTIVE INGREDIENT Stemdr Inc. (KR) 2022-04-06 EP claimed
WO-2020242133-A1 COMPOSITION FOR PREVENTING OR TREATING ASTHMA, RHINITIS OR CONJUNCTIVITIS, COMPRISING N-ACYL AMINO ACID AS ACTIVE INGREDIENT 전북대학교 산학협력단 2020-12-03 WO claimed
CN-111971037-A Compositions comprising N-acetyl or N-acyl amino acids for the treatment of atopy or pruritis 斯特姆德公司 2020-11-20 CN claimed
US-20200316001-A1 COMPOSITION FOR TREATING ATOPY OR PRURITUS CONTAINING N-ACETYL OR N-ACYLAMINO ACID STEMDR INC. (KR) 2020-10-08 US claimed
EP-3714880-A2 COMPOSITION FOR TREATING ATOPY OR PRURITUS COMPRISING N-ACETYL OR N-ACYL AMINO ACID Stemdr Inc. (KR) 2020-09-30 EP claimed
CN-110831584-A Targeted drug rescue with novel compositions, combinations and methods thereof 埃克塞瓦有限责任公司 2020-02-21 CN claimed
WO-2013155511-A1 DELIVERY OF PRESERVATIVES BY FOOD PACKAGING NEVADA NATURALS INC. (US) 2013-10-17 WO claimed
US-20130231389-A1 Delivery Of Preservatives By Food Packaging Nevada Naturals, Inc. (US) 2013-09-05 US claimed
EP-1435388-B1 D-aminoacylase mutants from Alcaligenes denitrificans for improved D-amino acid production. DAICEL CORP (JP) 2012-12-12 EP claimed
US-20040197880-A1 D-aminoacylase mutants DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2004-10-07 US claimed
EP-1435388-A2 D-aminoacylase mutants from Alcaligenes denitrificans for improved D-amino acid production. Daicel Chemical Industries, Ltd. (JP) 2004-07-07 EP claimed
US-6664083-B2 Adjusting stereospecificiy of amino acid seqences; obtain sample polypeptides, incubate with enzyme, recover stereospecific compound DAICHEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-12-16 US claimed
US-6437175-B2 MILD REACTION CONDITIONS AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) 2002-08-20 US claimed
US-20020102662-A1 Methods for racemizing N-acylamino acids and producing optically active amino acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-08-01 US claimed
EP-1130108-A1 Methods for racemizing N-acylamino acids and producing optically active amino acids Daicel Chemical Industries, Ltd. (JP) 2001-09-05 EP claimed
US-5892112-A ACYLATION OF AMINO ACIDS WITH ANHYDRIDES OR CARBOXY GROUPS, AMIDATION WITH AMINE AND CONVERSION OF ACID OR ESTER TO HYDROXAMIC ACID AND HYDROLYSIS GLYCOMED INCORPORATED (US) 1999-04-06 US claimed
US-4085207-A AND AT LEAST ONE OF N-ACYL-L-TRYPTOPHANS AND N-ACYL-L-PROLINES OTSUKA PHARMACEUTICAL FACTORY, INC. (JA) 1978-04-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197880-A1 D-aminoacylase mutants DAO, IL4I1, DDC MEN1 4296/4885KMT2A 782/4885ALOX15 1148/4885
US-20200316001-A1 COMPOSITION FOR TREATING ATOPY OR PRURITUS CONTAINING N-ACETYL OR N-ACYLAMINO ACID NAT1, AADAT, AANAT MEN1 4326/4885KMT2A 308/4885ALOX15 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.